Review
Copyright ©The Author(s) 2023.
World J Gastroenterol. Jan 7, 2023; 29(1): 43-60
Published online Jan 7, 2023. doi: 10.3748/wjg.v29.i1.43
Table 3 Summary of the studies that assessed radiomics to predict recurrence and treatment response in patient with hepatocellular cholangiocarcinoma who underwent surgery, liver transplantation or locoregional treatment
Ref.CountrynImaging modalityEndpointTreatment typeSegmentationROI/VOINo. of readersMain resultsValidation
Hui et al[100], 2018Singapore50MRIRecurrenceHepatic resectionManual, intratumoralROI3AUC: 0.78-0.84None
Kim et al[65], 2019South KoreaTraining: 128. Validation: 39MRIRecurrenceHepatic resectionSemiautomatic, intra- and peritumoralVOI2C-index: 0.716Internal
Zhao et al[101], 2021ChinaTraining: 78. Validation: 35MRIRecurrenceHepatic resectionManual, intratumoralVOI2AUC: 0.83 (training), 0.77 (validation)Internal
Zhou et al[68], 2017China215CTRecurrenceHepatic resectionManual, intratumoralROI2AUC: 0.84 (combined model)None
Ji et al[64], 2020ChinaInternal: 177. External: 118CTRecurrenceHepatic resectionManual, intratumoralVOI1AUC: 0.77 (internal), 0.78 (external)External
Guo et al[69], 2019ChinaTraining: 93. Validation: 40CTRecurrenceLiver transplantSemiautomatic, intratumoralROI1AUC: 0.79 (training), 0.79 (validation)Internal
Shan et al[66], 2019ChinaTraining: 109. Validation: 47CTRecurrenceHepatic resection or ablationManual, intra- and peritumoralROI2AUC: 0.80 (training), 0.79 (validation)Internal
Zheng et al[79], 2018ChinaTraining: 212. Validation: 107CTRecurrence and survivalHepatic resectionManual, intratumoralROI2AUC: 0.64 (training), 0.59 (validation)Internal
Song et al[67], 2020ChinaTraining: 110. Validation: 74MRIRecurrenceTACESemiautomatic, intra- and peritumoralVOI2C-index: 0.82Internal
Lv et al[71], 2021ChinaTraining: 40. Validation: 18MRIRecurrenceRFASemiautomatic, intratumoralVOI2AUC: 0.94 (training), 0.82 (validation)Internal
Sun et al[70], 2020ChinaTraining: 67. Validation: 17MRIRecurrenceTACEManual (intratumoral)VOI2AUC: 0.71-0.79Internal
Cai et al[75], 2019ChinaTraining: 80. Validation: 32CTLiver failureHepatic resectionSemiautomatic, intratumoralROI2AUC: 0.82 (training), 0.76 (validation)Internal
Zhu et al[76], 2020China101MRILiver failureHepatic resectionManual, entire liverROI2AUC: 0.81-0.89None
Ivanics et al[73], 2021Canada88CTTreatment responseTACEManual, intratumoralVOI1AUC: 0.70-0.87None
Kong et al[72], 2021ChinaTraining: 69. Validation: 30MRITreatment responseTACEManual, intratumoralVOI2AUC: 0.81 (training), 0.87 (validation)Internal
Chen et al[63], 2021ChinaTraining: 355. Internal: 118. External: 122CTTreatment responseTACESemiautomatic, intra- and peritumoralROI2AUC: 0.94 (internal), 0.90 (external)Internal and external
Horvat et al[74], 2021Brazil34MRITreatment responseRFAManual, intratumoralVOI1AUC: 0.76None